Introduction
Parathyroid hormone (PTH) is essential for regulation of calcium and phosphate homeostasis [1] . Intraoperative assessment of parathyroidectomy discloses a detectable half-life of approximately 3 min [2] . Accurate measurement of serum PTH levels is critical for the diagnosis of hyper-and hypoparathyroid disorders and for monitoring patients with chronic kidney disease.
Although PTH(1-84) is the biologically active hormone, PTH carboxyl fragments that lack the N-terminal amino acid sequence required for biological activity (i.e. PTH and others) are also present in the circulation as a result of glandular secretion or peripheral degradation of the hormone [3] .
Over the past 2-3 decades PTH immunoassays have progressed through a succession of generations resulting in increased specificity and trueness for detecting PTH. The commonly used intact PTH (iPTH) assays (second generation) not only measure the biologically active PTH(1-84) but also detect, to varying degrees, inactive fragments such as the PTH(7-84) fragments, and the measurements are thus widely variable [4, 5] . With the introduction of third-generation assays in which only the biologically active PTH(1-84) whole peptide is specifically targeted, greater specificity is realized enabling proper standardization, greater trueness and consistent measurements. Unlike third-generation PTH assays, intact PTH assays are not commutable due to their variable reactivity to inactive PTH(7-84) fragments [6] .
Against this historic composite, PTH stability studies to date have been performed with various outcomes attributable to assay variability, temperature and matrix parameters [7] . The need for a multifactorial study was confirmed in a recent study by Schleck et al. [8] whose study design was similar to ours. However, the present study design is more expansive using more patient types, more platforms and most importantly, longer storage times that best represent the current routine flow within the centralized U.S. laboratory system. Furthermore, traceability to the World Health Organization (WHO) International Standard was explored to determine trueness of the methods.
Materials and methods
The experimental design for the study is shown in Figure 1 : hemodialysis, primary hyperparathyroid or apparently healthy subjects (n = 5 each) were enrolled from three different sites: Saint Louis University, Henry Ford Hospital and LabCorp. For each patient, nine tubes (three time points for each of three sample types) were collected: (1) K 2 EDTA plastic lavender top vacutainers and centrifuged within 30 min of draw (plasma), (2) K 2 EDTA plastic lavender top vacutainers stored uncentrifuged (unspun plasma) and (3) serum separator gold top vacutainers centrifuged within 45-60 min to separate serum from the clot (SST). Tubes were stored at room temperature for 0, 24 or 72 h, followed by storage in 1 mL aliquots at −80 °C. Unspun tubes were centrifuged after storage immediately prior to aliquoting. Following collection, the frozen samples were shipped to LabCorp for PTH measurement on five different analyzers whose assay parameters are described in Table 1 . The data were analyzed by a multifactor analysis of variance fitted separately for each tube type, with storage duration and patient type as factors. Analytical variability, taken from the manufacturers' reported precision studies, was comparable between assays with repeatability parameters ranging from ~3 to 5 %CV or less, with the 1-84 PTH LIAISON assay having imprecisions of 3.1%-4.9% and 4.0%-7.2% for repeatability and reproducibility, respectively (Table 1) [9] . For trueness assessment, the WHO International Standard PTH(1-84), human, recombinant NIBSC code: 95/646 (Hertfordshire, UK) [10, 11] , or Bachem synthetic PTH(1-84) (PN H-1370, Torrance, CA, USA) was spiked into charcoal-stripped, heat-inactivated human serum at concentrations ranging from 0 to 1000 pg/ mL. The samples were analyzed for PTH content by the different methods. The distribution of inactive PTH fragment was assessed in 1533 hemodialysis patients by measuring both PTH(1-84) with the LIAISON method, and iPTH with Method A because of its high cross-reactivity with inactive fragments [4] . The fragment content was calculated as (iPTH-PTH(1-84))/iPTH and expressed as % of total iPTH.
The study protocol was approved by the respective Institutional Review Boards of the respective sites.
Results
One of the major criticisms of commercial PTH assays has been that none of the intact PTH assays have been calibrated to the 95/646 WHO PTH1-84 standard [12] . This is largely due to the detection of PTH fragments in the iPTH assays. The data in Figure 2 show WHO standards prepared at concentrations ranging between 0 and 1000 pg/ mL and the corresponding measured values of PTH derived from the different methods. The LIAISON 1-84 PTH measures the WHO recombinant PTH(1-84) standard with little bias as evidenced by its close alignment with the line of identity, thereby corroborating the reliable standardization, calibration and commutability of this FDA-approved assay. Closely aligned data were observed when trueness was assessed using the synthetic Bachem PTH(1-84) standard (data not shown).
All samples in the stability study were normalized to the time = 0 h plasma sample for analysis. In Figure 3 , average deviations for all 15 patients from the baseline plasma sample at each time point are plotted for the five different platforms and three sample types. Box-Cox methodology recommended that the analysis be made on log-transformed values, which are shown on the y-axes of these plots. Table 2 presents the same data expressed as % change from the plasma sample (T = 0 h). Little variability was observed for plasma and unspun plasma over the first 24-h storage period for the PTH(1-84) and iPTH on the LIAISON analyzers and for iPTH by Method B. Method A and Method C were more variable but not significantly different from baseline for plasma and unspun plasma. Most notable, however, is that serum is significantly less stable than plasma when samples are stored at room temperature for 72 h regardless of platform, even when separated from the clot by centrifugation within 1 h. The stability of PTH in unspun plasma for 72 h at room temperature was confirmed in an independent study with hemodialysis patients, where the levels of PTH(1-84) were 99% ± 5% from the The log-transformed values of the ratio of measurement to the reference value (plasma at T = 0 h) were plotted as an average with 95% confidence interval for the 15 subjects in the study for each sample type and storage time. The corresponding values expressed in percent change are shown in Table 2 .
T = 0 sample and levels of iPTH were 97% ± 6% (data not shown). Multifactor analysis of variance (Table 3) indicates statistical significance at the 5%, 1% and 0.1% levels. Although some of the marginally statistically significant differences may be explained as Type I errors from multiple testing, the larger significant effects observed across the board for SST samples stored at room temperature for 72 h likely represent true instability. Method A and Method C show the largest effects, which are likely a combination of both sample instability and assay imprecision.
Discussion
In the present study, we found that PTH is stable for up to 72 h in EDTA plasma from hemodialysis, primary hyperparathyroid and apparently healthy subjects across a wide range of PTH levels. Blood collected in K 2 EDTA plastic lavender top vacutainers stored uncentrifuged at room temperature for up to 72 h, and then centrifuged, also demonstrated remarkable PTH stability.
Serum provides a convenient sample type for PTH testing because its collection obviates the need for collecting a second sample for other tests that are frequently Table 2 : Percent change from the baseline plasma sample corresponding to the log transformed data in Figure 3 . 102% 95%-108% 96% 91%-101% 93% 80%-106% 98% 93%-103% 125% 104%-145% 72 h 96% 88%-104% 95% 88%-103% 95% 84%-106% 97% 92%-102% 133% 104%-162% Unspun plasma 0 h 107% 104%-110% 108% 103%-112% 103% 91%-115% 106% 102%-110% 109% 97%-121% 24 h 101% 94%-107% 105% 99%-112% 101% 88%-114% 100% 96%-105% 116% 103%-129% 72 h 101% 94%-109% 102% 92%-112% 95% 84%-105% 99% 93%-105% 122% 95%-149% SST 0 h 107% 101%-114% 111% 103%-120% 110% 94%-127% 104% 99%-108% 92% 77%-107% 24 h 99% 91%-107% 101% 92%-110% 89% 75%-103% 99% 92%-107% 82% 66%-98% 72 h 82% 73%-89% 82% 72%-91% 72% 59%-84% 86% 79%-93% 78% 65%-91% ordered concomitantly (calcium, vitamin D metabolites). However, PTH measurements from unfrozen serum samples are accurate only if testing is performed within 24 h of collection. Alternatively, serum can be frozen at collection for subsequent testing on site or at a centralized laboratory. The advantage of testing from a single matrix is countered by the extra effort required for transferring serum to a secondary container, freezing the samples and thawing/mixing the sample prior to testing. In recognition of this, laboratories might consider collecting an EDTA whole blood sample for transfer at the point of collection for local testing or transportation to a central laboratory for processing and testing. Although results generated by three of the five methods evaluated were quite consistent, two methods exhibited greater variability as revealed by their much larger confidence intervals ( Figure 3 ). Methods A and C have greater cross-reactivity to the PTH(7-84) fragments that are known to be present at higher levels in hemodialysis patients [13] . Because greater instability in hemodialysis vs. normal or PHPT samples was not observed (data not shown), the larger confidence intervals likely represent a greater inherent imprecision of these two assays that is well beyond their stated analytical variability.
Our statistical approach, multifactor analysis of variance, differs from the approach taken by Schleck et al. [8] . Significant observations in the multifactor setup (given by multiple patient types, multiple sample matrices, multiple storage durations and multiple assay platforms) are best identified using a multiway analysis, which better controls Type I error rates, and borrows strength by pooling information from different cells, which enables more power [14] . By contrast, doing a collection of paired tests between these different combinations of factors can lead to false positives (Type I error) due to the multiplicity of all the test statistics generated, and at the same time lose power resulting in a failure to identify factors that actually matter (Type II errors).
PTH assays are notably quite erratic and provide dissimilar values depending upon the manufacturer's utilization of components with widely variable fragment cross-reactivity and different standardization regimens [4] . In this study, average PTH values were 101, 274, 238, 189 and 189 pg/mL for the LIAISON 1-84 PTH, LIAISON N-TACT and Methods A, B and C, respectively. Although efforts by the PTH working group to standardize PTH assays are ongoing, transitioning to the third-generation PTH assays affords immediate opportunity for true and standardized measurements, as these PTH(1-84) specific assays can be aligned with WHO recombinant standards [11] as well as synthetic PTH . In hemodialysis patients, there is a wide distribution of percent PTHfragment content (Figure 4 ). These representative data from 1533 hemodialysis samples illustrate that patients with similar levels of iPTH and quite different levels of active PTH(1-84) will respond differently to treatment, emphasizing the importance of measuring the active molecule with third-generation assays that are standardized and accurate.
Although the strength of our study resides in the statistical analysis and extended storage times, its major limitation was the inability to normalize to plasma samples collected and measured immediately without freezing [6] . The design of this study engaged multisite collection and centralized testing, which did not allow for such a control. Although Cavalier et al. showed average declines of ~16% and ~26% in iPTH assays following 1 and 3 months storage at −80 °C, respectively, in this study the samples were all processed similarly to mitigate or effectively normalize the effects of freezing. Competing interests: The funding organization(s) played a role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
